The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions
CERSCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transf
Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025
CERSCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of the company’s website at ir.cerus.com/events-and-presentations/events-and-webcasts/. A replay will be available for 30 days after the event. ABOUT CERUS Cerus C
Cerus Corporation Announces Second Quarter 2025 Financial Results
CERSCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter’s commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generati
Cerus Corporation Celebrates World Blood Donor Day 2025
CERSCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year’s theme, “Give blood, give hope: together we save lives” is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and exp
Cerus To Showcase Latest INTERCEPT Blood System Clinical Data At 35th Regional ISBT Congress Being Held May 31 To June 4, 2025, In Milan
CERSCerus Announces Two In-Country Regulatory Approvals For INT200
CERSCerus Affirms FY2025 Sales Guidance of $194.00M-$200.00M vs $221.92M Est
CERSCerus Q1 EPS $(0.04), Inline, Sales $43.24M Miss $49.62M Estimate
CERSA Look at Cerus's Upcoming Earnings Report
CERSCantor Fitzgerald Reiterates Overweight on Cerus, Maintains $4 Price Target
CERSCerus Q4 2024 GAAP EPS $(0.01), Inline, Sales $56.75M Beat $49.64M Estimate
CERSCerus Announces Preliminary 2024 Revenues Of $180.3M, Up 15% From 2023; 2025 Revenue Projected At $194M-$200M, Indicating 8%-11% Growth; IFC Revenue Grows 42% In 2024; 2025 IFC Revenue Predicted Between $12M-$15M; Anticipates LED Illuminator Launch In Eur
CERSCerus Corp. Reports New Manufacturing, Supply Deal With Fresenius Kabi For INTERCEPT Blood System Sets, No Terms Disclosed
CERS